Rising Prevalence of Diabetic and Obese Population Globally
The increasing global prevalence of diabetic and obese population particularly in the developed markets is expected to raise the NASH therapeutics and diagnostics market. An estimated 5-20% of the population accounting for nearly 15 million, shows the prevalence of NASH consuming fatty acids diet in the United States, which is driven by obesity and diabetes. In the United Kingdom, as per the Diabetes Community, 2015, over four million people were diagnosed with diabetes which represented 6% of the United Kingdom’s population, i.e., one in every 16. With that, the United Kingdom had the fifth highest rate of obesity in Europe in 2015, with nearly 25% of the population having body mass index of 30 or more. A similar trend or higher could be found in several developed countries, which raises the demand for NASH therapeutics and diagnostics market.
Other factors driving this market are the lucrative pipeline for NASH therapeutics and emergence of novel biomarkers and improvement in liver biopsy technologies.
Slow Advances in the Therapeutic Field
One of the primary hindrances for NASH therapeutics and diagnostics market is the slow advancements in the therapeutic field. According to an article published in 2015, in the Journal of Hepatology, there is no approved drug for NASH even after the 35 years of its formal description and 15 years of intense research worldwide. Although there are several drugs in the pipeline but the process of approving the drug to next phase has been slow. The wide range of multiple pathogenic mechanisms hinders the success rate of the drugs in clinical trials. Thus, restricting the growth of this market.
Another factor impeding this market is the lack of effective diagnostics for NAFLD.
North America to Dominate the Market
North America is set to dominate the market in the period from 2018 to 2023 for NASH therapeutics and diagnostics. The well-established healthcare infrastructure with high preference to research and development activities makes the United States a region with high opportunities for growth and long-term establishment for companies. With that, the large number of prevailing cases of high cholesterol and change in lifestyle plays a vital role in the growth of this market.
Key Developments in the Market
- April 2018 - AstraZeneca licensed IONIS-AZ6-2.5-LRx, NASH drug from Ionis Pharmaceuticals, Inc. for USD 30 million.
- December 2017 - NorthSea Therapeutics B.V. completed a EUR 25 million Series A funding for the development of icosabutate, an oral promising drug candidate for the treatment of NASH.
Reasons to Purchase the Report
- Current and future of global nonalcoholic steatohepatitis therapeutics and diagnostics market outlook in the developed and emerging markets.
- Analysis of various perspectives of the market with the help of Porter’s Five Forces Analysis.
- The segment that is expected to dominate the market.
- Regions that are expected to witness the fastest growth during the forecast period.
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the Market Estimate sheet (in Excel).
This report can be customized to meet your requirements. Please contact us for more information.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry
6. Market Dynamics
6.1.1 Lucrative Pipeline for NASH Therapeutics
6.1.2 Rising Prevalence of Diabetic and Obese Population Globally
6.1.3 Emergence of Novel Biomarker Technologies and Improvement in Liver Biopsy Technologies
6.2.1 Lack of Effective Diagnostics for Non Alcoholic Fatty Liver Disease (NAFLD)
6.2.2 Slow Advances in the Therapeutic Field
6.4 Key Challenges
7. Market Segmentation
7.1 By Therapeutics
7.1.1 Phase III
188.8.131.52 Obeticholic Acid (OCA)
184.108.40.206 Aramchol (arachidyl amido cholanoic acid)
7.2 By Diagnostics Technqiues
220.127.116.11 Ultrasonography (US)
18.104.22.168 Computed Tomography (CT)
22.214.171.124 Magnetic Resonance Imaging (MRI)
7.2.2 Liver Biopsy
7.2.3 Biomarker diagnostics
126.96.36.199 Serum Biomarkers
188.8.131.52 Hepatic Fibrosis Biomarkers
184.108.40.206 Apoptosis Biomarkers
220.127.116.11 Oxidative Stress Biomarkers
7.2.4 Other Diagnostics
7.3 By Treatment Therapies
7.3.1 Pharmacologic Therapy
7.3.2 Steatosis/insulin Resistance
7.3.4 Surgical Interventions
7.4 By Geography
7.4.1 North America
18.104.22.168 United States
22.214.171.124 Rest of North America
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
7.4.4 Middle East & Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle East & Africa
7.4.5 South America
126.96.36.199 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 AstraZeneca PLC
9.2 Conatus Pharmaceuticals, Inc.
9.3 Enzo Biochem, Inc.
9.4 Galmed Pharmaceuticals Ltd
9.5 Genfit Corp.
9.7 Horizon Pharma PLC
9.9 Intercept Pharmaceuticals, Inc.
9.10 Novo Nordisk A/S
*List not Exhaustive
10. Future of the Market